drugset / Trial / NCT00003765

O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors

NCT00003765

Phase 1 Completed 36 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of O6-benzylguanine and carmustine in treating children who have refractory CNS tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

Timeline

Start
1999-05
Primary completion
2006-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject O6-benzylguanine Small molecule 120 mg/m2 Intravenous
Subject carmustine Small molecule 58 mg/m2 Intravenous